Dietrich Stephan, NeuBase Therapeutics CEO

NeuBase lays off 60% of em­ploy­ees as it swaps out an­ti­sense fo­cus for gene edit­ing tech en­dorsed by George Church

Ge­neti­cist and se­r­i­al en­tre­pre­neur Di­et­rich Stephan had hoped that his an­ti­sense oligonu­cleotide plat­form at NeuBase Ther­a­peu­tics could ex­pand the field that Io­n­is pi­o­neered to new ar­eas. But in the end, he con­clud­ed now is not the right time to ex­plore it.

NeuBase has de­cid­ed to shift its whole fo­cus to gene edit­ing, de­fer­ring pre­clin­i­cal ac­tiv­i­ties for an­ti­sense pro­grams tar­get­ing my­oton­ic dy­s­tro­phy type 1, Hunt­ing­ton’s dis­ease and KRAS-mu­tant can­cers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.